1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results
1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results
复制标题
NG-350A 的 1011P FORTITUDE I 期研究，一种表达抗 CD40 激动剂抗体的新型肿瘤选择性腺病毒载体：单药治疗剂量递增结果
作者：
A. Naing;L. Rosen;R. Camidge;D. Khalil;J. Davies;D. Miles;M. Patel;P. Cockle;B. Champion;D. Krige;T. Lillie
